A Case of Successful Treatment of Refractory Synovitis Acne Pustulosis Hyperostosis Osteitis (SAPHO) Syndrome with Adalimumab.
10.12701/yujm.2013.30.1.55
- Author:
Jin Taek YOO
1
;
Young Hwan KIM
;
Soon Myung JUNG
;
Sang Chang KWON
;
Seung Min RYU
;
Jun Ouk HA
;
Joung Wook LEE
Author Information
1. Department of Internal Medicine, St. Mary's Medical Center, Busan, Korea. cuatop@daum.net
- Publication Type:Case Report
- Keywords:
SAPHO syndrome;
Treatment;
Adalimumab
- MeSH:
Acne Vulgaris;
Acquired Hyperostosis Syndrome;
Acromioclavicular Joint;
Antibodies, Monoclonal, Humanized;
Arthralgia;
Bacteria;
Diclofenac;
Diphosphonates;
Follow-Up Studies;
Humans;
Hyperostosis;
Joints;
Methotrexate;
Osteitis;
Rare Diseases;
Recurrence;
Skin;
Sulfasalazine;
Synovitis;
Adalimumab
- From:Yeungnam University Journal of Medicine
2013;30(1):55-57
- CountryRepublic of Korea
- Language:English
-
Abstract:
Synovitis acne pustulosis hyperostosis osteitis (SAPHO) syndrome is a rare disease that involves the skin, bones and joints. It is thought to be caused by infection with low-toxicity bacteria and to be the result of reactive infectious osteitis. However, this hypothesis has not yet been clearly established. New SAPHO syndrome treatment methods are needed because the disease does not respond to treatment in many cases. In this paper, a case is reported of SAPHO syndrome with pain in the acromioclavicular joint and with squamous and pustular macules on the palms and soles. First, the patient was treated with aceclofenac, prednisolon and sulfasalazine for two weeks. However, the symptoms were not relieved, so methotrexate and pamidronate were added to the treatment. Since no improvement was seen after four weeks of treatment, adalimumab was prescribed. The skin lesions were relieved two weeks later, and the bone pain and arthralgia, four weeks later. No recurrence or adverse effects were observed at the 22-week follow-up.
